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ORIGINAL RESEARCH
Objective: Estimate the costs and benefits of influenza vaccination in a group of employees
of an Italian District Health Authority, Unità Locale Socio Sanitaria (ULSS), to define a
scheme of an economic evaluation to be used for other vaccination strategies.
Design: In an observational study conducted from December 2002 to April 2003, 107 ULSS
employees, voluntarily vaccinated, were compared with 107 nonvaccinated ULSS employees
matched for age, sex, and job category. The outcome of cost-benefit analysis was evaluated
by checking personnel department records about absences from work and their causes, including
influenza. Costs and benefits of the influenza vaccination from the ULSS point of view were
calculated.
Results: The influenza vaccination strategy reduced absences from work by 23% and decreased
the loss of working days by 30% and related cost. This difference is not significative. The
ratio vaccination benefits/cost was €4.2. The advantage of vaccination is confirmed by
sensitivity analysis performed on the mean cost of a working day, which showed that the
benefit-cost ratio ranged from €4.5 to €11.7.
Conclusions: The results suggest that the influenza vaccination strategy in our sample of
people was cost-saving. The economic evaluation used in this study could also be used for
other vaccination strategies and in other settings.
Keywords: economic evaluation, influenza vaccination strategy, observational study
Introduction
Influenza is a substantial epidemiological problem because of its ubiquity and
contagiousness, the antigenic variability of its viruses and its possible serious
complications. As an infectious illness, it is the third cause of death in the advanced
economy countries, preceded only by HIV and tuberculosis (Bridges et al 2003).
Because of the high mortality and morbidity rates (Landi et al 2003) in high-risk
populations, its economic burden for society can be heavy.
Anti-influenza prophylaxis as long been widely suggested for risk categories
such as people older than 64 years (Nichol and Goodman 1999; Gasparini et al 2002;
Allsup et al 2003). At present, the effectiveness of flu prevention is normally evaluated
on people of all ages who want both to avoid the disease, and to help in break the
chain of infection, achieving in this way substantial reductions in morbidity (Gallo
et al 2002; Rychlik et al 2003; Turner at al 2003; Principi and Esposito 2004).
Several studies have evaluated the economic burden of influenza in target
populations: evidence from a review of influenza-related costs is the extent of indirect
cost (loss of production) in proportion to the total cost of the illness, accounting for
70%–90% of influenza-related costs (Levy 1996; Kumpulainen and Makela 1997;
Keech et al 1998; Postma et al 1999; Gasparini et al 2000; Nichol et al 2003).
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These assumptions are confirmed by the growing interest
in economic evaluation of prevention strategies for the
healthy working population (Nichol et al 1995; Postma et
al 2002; Akazawa et al 2003). In this target population, the
effect of vaccination is particularly important because it
reduces the number of working days lost due to influenza
and, from society’s perspective, can lower the costs of loss
of production that may be considered an economic benefit
of the vaccination itself.
The Italian Health Ministry (Ministero della Salute 2003)
advised that, with the aim of reducing morbidity of influenza
and its complications, district public health structures must
offer influenza vaccination to: people aged 65 years or older;
children or adults with chronic respiratory, cardiovascular,
uropoietic diseases, hemopoietic organ diseases, diabetes
or other metabolic diseases, intestinal diseases, cystic
fibrosis, HIV or other immune system diseases; people
undergoing surgery; people working in public offices of high
public interest; people working as nursing staff for high-
risk patients, or their relatives; rheumatic children with
pathologies requiring prolonged treatment with
acetylsalicylic acid and running the risk of Reye’s syndrome.
The aim of this study was to estimate the cost and benefits
of a preventive influenza vaccination campaign in the
employees of an Italian district healthcare unit, Unità Locale
Socio Sanitaria n°17 (ULSS), from the employer’s point of
view, in order to define a cost-benefit analysis scheme to be
used for other strategies of vaccination and in other settings.
Two cohorts of employees were analysed (vaccinated and
not vaccinated) calculating the losses of production due to
influenza and all the total costs related to the vaccination.
Methods
In this observational study, conducted from December 2002
to April 2003, 107 employees who voluntarily received the
vaccination were compared with 107 nonvaccinated
employees matched for age, sex and job category, working
in the same healthcare unit (10.9% of the total staff of
ULSS). In order to assess absences related to influenza-like
illness (ILI) according to the WHO definition of influenza,
employees were contacted by telephone at the end of the
epidemic period.
To select the observation period, we analysed the
incidence of flu per age group during the 2002/2003
epidemic season (Figure 1). In that season, according to the
Ministry of Health epidemiological observatory (Ministero
della Salute 2003), ILI patterns differed from the previous
three seasons: the incidence was low up till the last weeks
of 2002 and started rising in the last week (like during 2000–
2001, but later than during 1999–2000 and 2001–2002).
From available data, it was decided only to consider cases
arising from 1 December 2002 to 15 April 2003.
Cost analysis
Economic evaluation of the vaccination program was
performed from the perspective of the employer, focusing
on the direct vaccination program costs, including the cost
of vaccines, materials, and cost of administration; indirect
Abbreviations: ILI: influenza-like illness.
Figure 1 Season 2002–2003: incidence (/10 000) of ILI by age group.Therapeutics and Clinical Risk Management 2006:2(2) 221
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costs of the vaccination program, including time for the
employees to get the vaccine, sick leave, with or without
temporary replacement of the employee (Table 1). The cost
of these outcomes to the employer were estimated by
considering salaries as well as the loss of income caused by
the employee’s absence or illness.
The economic evaluation was done from the ULSS
perspective. Cost of vaccination was established
considering:
• Purchase price €4.774 (vaccine used: split, Aventis-
Pasteur, source ULSS n° 17);
• Physician’s time to administer vaccines: 5 minutes, based
on the physician annual gross salary (eg, the cost to
ULSS n° 17 per employee);
• Nurse’s time to assist the physician: 5 minutes, based
on the nurse’s annual gross salary;
• Time spent by employees to receive vaccine: 15 minutes,
using the annual gross salary of each employee;
• Costs of preparation and executing the vaccine
administration were estimated as a lump-sum amounting
to €0.103 per patient.
The net economic benefit (CS) of the vaccination
program was calculated using the following formula: CS =
(cost of ILI in nonvaccinated employees) – (cost of ILI in
vaccinated employees + cost of vaccination program).
Benefits of vaccinations were estimated as the reduction
of production losses according to the Human Capital Method
(Freund and Dittus 1992; Sloan 1995). The use of healthcare
program can be viewed as an investment in a person’s human
capital. In measuring the return on this investment, the value
of the healthy time produced can be quantified in terms of
the person’s renewed or increased production in the
marketplace.
To assess the value of one lost working day, we used the
mean annual labour cost to the ULSS n° 17 for each job
category. This value was obtained by adding the gross wage
to fiscal drag (about 28% of gross wage) and IRAP (Imposta
Regionale sulle Attività Produttive), a regional tax
corresponding to 8.5% of gross wage) and dividing it by
220 working days (average working days per year in Italy).
As the analysis was done from the employers’
perspective, costs sustained by sick employees for drugs,
tests, physician visits, and hospitalizations were not
considered. Sensitivity analysis was done on the labour cost:
three scenarios were envisaged, valuing all absences with
the same cost (in the vaccinated cohort and the control one)
using minimum, base, and maximum labour costs.
Cost-effectiveness analysis
The reduction of the incidence of influenza among
employees was considered in analyzing data collected at
follow-up. Being the two cohorts of the same size the
effectiveness of vaccination was calculated using the
formula:
(Sick employees among nonvaccinated – sick employees among vaccinated) x 100
Sick employees among nonvaccinated
or from the reduction in the number of working days lost.
Statistics
The control cohort was extracted from the total of
nonvaccinated employees according to a random stratified
sampling procedure. Three strata were selected: sex, age
(under or over 40 years) and job category. The aim was to
obtain homogeneous samples according to income, ie
according to unit’s labour cost. The association between two
Table 1 Source and calculation for economic data
Economic items Economic evaluation
Vaccination program: direct costs
Cost of vaccines and materials Purchasing prices
Cost of administration by nurse Time x hourly labor costs
Vaccination program: indirect costs
Cost of average time lost by employees for vaccination Time (15 min) x minute cost of individual labor
Cost of working days lost due to adverse events Time x  day cost of individual labor
Vaccination program: indirect benefits
Cost of sick leaves due to ILI avoided Number of days x day cost of individual labor
ILI: indirect costs
Cost of sick leaves Number of days x day cost of individual labor
Abbreviations: ILI, influenza-like illness.Therapeutics and Clinical Risk Management 2006:2(2) 222
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quantitative variables was estimated by using the Pearson
linear correlation coefficient or Spearman when Pearson’s
coefficient was not applicable. Pearson’s chi-square test was
used to verify homogeneity between cohorts of stratum
variables; t-test for independent samples was used to
compare age, logarithmic transformation of average daily
cost (costs were transformed to obtain a normal distribution),
and observed outcomes.
Results
The total number of people who declared to have had the
flu is 55: 24 (22.42 %) of the vaccinated cohort and 31 (28.97
%) of the nonvaccinated cohort. The total working days lost
due to flu have been 161 for the first and 231 for the second
one. This means that also if this difference (30.3 %) is not
significant (p=0.329) it is relevant.
The sampling methods gave two homogeneous cohorts,
summarized in Table 2. The mean age was similar in the
vaccinated and nonvaccinated groups. Among vaccinated
employees, 32% were males while in nonvaccinated males
were about 25% (not significant, p=0.289). Mean labour
cost of the two cohorts was close to €200.
Total cost of vaccination was about €1866, for an average
of €17.45 per patient (Table 3). Administration of the
vaccines took about ten hours of the medical staff
(physicians and nurses were all ULSS n°17 employees) for
a total cost of €506.65 for the doctor and €182.44 for the
nurse.
Time spent by employees to receive vaccine was valued,
using the mean hourly cost per job category of the enrolled
employees, at €656.04 (35% of the total cost) – sources
ULSS n° 17. The direct cost of the vaccine is 27% of the
total cost.
These data confirm the importance of indirect costs (loss
of production) amounting to than 70% of the total cost of
the vaccination program.
Costs for preparation, carrying out the vaccination and
waste disposal were evaluated in 11.05. Stocking cost was
not considered because there was already a refrigerator in
the physicians office; the cost of the vaccination campaign
among employees was not considered either, because it was
irrelevant.
Table 4 shows that 24 vaccinated employees were absent
for influenza, totalling 161 working days lost, while 31
nonvaccinated people lost 231 working days. The vaccinated
cohort was absent 1.5 days on average and the nonvaccinated
cohort 2.2 days, for a reduction of 32% (ns).
Using the mean cost of a working day per job category
to measure the economic impact of the absences, the total
cost was €39 250 for the nonvaccinated cohort and €31 840
for the vaccinated one. The mean cost of each working day
lost by nonvaccinated employees was lower than the
vaccinated group.
The vaccination appeared to reduce days of absence from
work, but the differences between the groups were not
statistical significant.
Vaccination cost (€1866.99) must be added to the cost
of production lost to get the total cost of vaccinated
employees, ie €33 347, saving about €55 per employee for
a total of €5900 (Table 5).
The cost–benefit ratio for this vaccination program is
€4.2, meaning €1 invested returns €4 saved through less
absenteeism from work.
Results show the vaccine reduced the incidence of
influenza with about 23% fewer working absences due to
influenza and a shorter duration of the absences (6.7 days
for vaccinated employees and 7.5 for not vaccinated).
Comparing results between cohorts, we noticed that
absent employees in the nonvaccinated group had a lower
Table 2 Population characteristics
Vaccinated Non- p value
n=107 vaccinated
n=107
Age (mean ± SD) 44.3 43.2 0.376
Age (min-max) 24-62 26-60
Males 31.8% 25.2% 0.289
Managers 16.8% 18.7% 0.935
Employees 19.6% 19.6% 0.935
Manual workers 63.6% 61.7% 0.935
Mean cost of one
 working day (€) 196.20 202.36 0.741
Abbreviations: max, maximum; min, minimum; SD, standard deviation.
Table 3 Cost of anti-influenza vaccination (n=107)
Cost items Total %
Vaccine (€ 4.774 x 107 pts) 510.82 27.4%
Physician (€ 4.735 x 107 pts) 506.65 27.1%
Nurse (€ 1.705 x 107 pz) 182.44 9.8%
Working time lost 656.04 35.1%
Preparation, carrying out and waste
discharging 11.05 0.6%
Total vaccination costs  €1866.99 100%Therapeutics and Clinical Risk Management 2006:2(2) 223
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mean daily cost than the vaccinated group (€169.91 vs
€195.53).
Among the costs, purchase of the vaccine was only 27%
of the total cost and time lost by employees was the
component weighing most in the vaccination program’s
costs (about 35%).
Sensitivity analysis
A univariate sensitivity analysis was performed. This
analysis was done on the average daily cost of labour,
establishing a single value for each employee and testing
how the cost–benefit ratio changes. Analysis was conducted
assuming a minimum of €100, an average of €180 and a
maximum of €460, corresponding to annual costs of
€22 000, €40 000 and €100 000. Results are summarized in
Table 6: the cost–benefit ratio rises from €4.5 to €11.7 from
the minimum to the maximum scenario. The higher cost of
an absent person salary determines an increase of the benefit
of the vaccination program (from €65.42 to €300.93).
Discussion
During the peak of incidence, flu determines a high
number of working absence with a reduction of
productivity of ill people (Nichol et al 1995; Campbell
and Rumley 1997; Keech et al 1998; Nicholson 1998;
Olsen et al 1998; Wilde et al 1999). This reduction of
productivity is not caused by illness in high risk people,
but by illness in normally healthy adult people of working
age. About 50% of working absences is caused by flu in
manual workers aged between 25 and 44 years (Gardener
and Schaffner 1993; Campbell and Rumley 1997). This
study evaluated costs and benefits, from a district public
healthcare unit’s (ULSS n° 17) perspective, of an
influenza vaccination strategy among the unit’s
employees. Vaccination costs, such as purchase price,
time spent by the physician, nurse and employees for
vaccination, preparation, carrying out and disposal costs,
and benefits (less absenteeism and lost productivity
according to Human Capital Methods [Freund and Dittus
1992; Sloan 1995]) were calculated in each cohort.
The research findings emphasize that the influenza
vaccination brings benefits: there is a reduction of working
day absence and the duration of absence. Such reduction
therefore allows a contraction of indirect costs, which differ
from 31 479 of vaccinated employees to 39 250 of the
nonvaccinated group. Clearly, considering the direct costs
of vaccination, this difference is reduced, but a net
economical benefit of vaccination remains. This reduction
is not statistically significant. Another important aspect to
take into consideration is that costs for the cure of influenza
have not been valued, including the possible hospitalization
of critical cases, as only the expenses sustained by the ULSS
have been considered, instead of the expenses sustained by
the employees.
Table 4 Number of absent employees, lost working days and total costs due to influenza-related absences
Vaccinated Non-
(a) vaccinated Differences Differences %
(b) (b-a) (b-a)/b x 100 p value
Employees (n) 107 107 - - -
Employees absent (n) 24 31 7.00 22.6% 0.317
Working days lost (n) 161 231 70.00 30.3% 0.329
Mean duration of absence per absent employee (days) 6.7 7.5 0.74 10.0% -
Mean duration of absence per employee (days) 1.5 2.2 0.65 30.3% -
Total cost of the absences  € 31, 479.55 39, 250.00 7, 770.45 19.8% 0.444
Mean daily cost of the absence  € 195.53 169.91 (25.61) -15.1% 0.922
Table 5 Results (mean values n=107)
Total Per employee
Vaccinated Nonvaccinated Difference Vaccinated Nonvaccinated Difference
(a) (b) (b-a) (a) (b) (b-a)
Vaccination costs (€)  1,866.99  - -1,866.99  17.45  - -17.45
Absence costs (€)  31,479.55  39,250.00  7,770.45  294.20  366.82  72.62
Total cost (€)  33,346.53  39,250.00  5,903.47  311.65  366.82  55.17Therapeutics and Clinical Risk Management 2006:2(2) 224
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Some Italian studies have assessed vaccination costs
among working age people (Colombo et al 2001) and among
the elderly (Gasparini et al 2003; Montomoli et al 2003)
(Table 6). The cost of a vaccination program in a private
company was €16.27, which is very close to that calculated
in our study but with a different cost distribution. The
vaccine cost more than in our study (67% of total cost),
probably because it was purchased by a private company,
but the cost of time lost by employees to receive the vaccine
was much lower (10% vs 35% in our study). The cost for
the elderly ranged from €10–15, 45% of which is the cost
of the vaccine.
This confirms that the cost of vaccine is only a small
component of the total expenditure for a prevention
campaign, while the cost of employees’ time spent to receive
or to administer vaccine is more substantial.
Net savings from anti-influenza vaccination is about €55
per employee (the total cost for 107 employees is more than
€5900); benefit, ie lower cost of fewer absences, is €72.62
per employee (the mean cost of absences of the
nonvaccinated cohort was about €367 compared with €294
for vaccinated staff).
Cost–benefit analysis gave benefit-cost ratio of €4.2, ie
€1 invested returns €4.2, measured by the cost of lower
absenteeism, to the district healthcare unit. This study
measured benefit as lower cost and fewer absences from
work. If effectiveness is the same, ie same number of days
lost in each cohort, the benefit could depend only on the
cost of work (that is part of the cost of the vaccination
program too because of the time spent to receive or
administer the vaccine).
Sensitivity analysis showed that in the “minimum”
scenarios, as the cost of a working day was the same in
both cohorts, the cost-benefit ratio was higher than in the
base case, in which the cost of the nonvaccinated group
was lower.
It can be argued that the higher the labour cost, the greater
the cost–benefit ratio of this influenza vaccination program,
assuming the same level of effectiveness of the vaccine. In
this study benefit from less productivity lost ranged from
€65 to €300, depending on the mean salary of each
vaccinated employee (from €22 000 to €100 000 yearly).
The Human Capital Method approach might
overestimate indirect costs. The friction cost method
(Koopmanschap et al 1995; Johannesson and Karlsson 1997;
Koopmanschap and Rutten 1996a, 1998b) considers that
when an employee is absent, not all the production will be
lost because the absence is compensated by another
employee or when the employee comes back to work.
Introducing some compensation mechanisms to estimate
production lost is a good way to evaluate absences of high
job categories such as managers because it can be assumed
that time lost due to illness will in fact be made up by the
employee himself, avoiding any real loss of production as
assumed by the Human Capital Method. The friction cost
method usually reduces the evaluation of the cost of
absenteeism, so in our study the benefit from vaccination
could be overestimated.
This analysis adopted the ULSS n° 17 perspective, so it
did not consider the costs of treating patients because they
are sustained by patient himself or by the SSN (Sistema
Sanitario Nazionale – National Health Service). This means
the results are conservative because of the benefit from
reduced healthcare consumption to treat influenza and its
complications due to the lower incidence of illness in the
vaccinated cohort.
In other countries, many studies on costs and benefits
of the annual of influenza vaccination programmes
demonstrated the economical benefit of vaccination to the
employer. A review of 11 health economics studies carried
out between year 1979 and 2000 pointed out that 8 studies
showed a clear benefit of the vaccination to the employees
(Postma et al 2002).
Failure to show any benefit was linked to high
vaccination costs, low incidence rate of influenza, or the
short duration of sick leave. In the reviewed studies where
cost benefits were found, they mostly resulted from indirect
cost savings such as losses arising from absenteeism or low
levels of production (Postma et al 2002). In fact, such
indirect costs are the most important considerations for the
benefits of such vaccination programs (Postma et al 2002;
Akazawa et al 2003). Other health economic analyses have
shown benefits of vaccination programs where influenza
rate among the workforce are as low as 2% and that
Table 6 Sensitivity analysis
Cost and benefits Mean value per
employee (€)
Cost of vaccination - min 14.4
Cost of vaccination - base 16.9
Cost of vaccination - max 25.7
Benefit - min 65.4
Benefit - base 117.8
Benefit - max 300.9
Benefit/cost ratio - min 4.5
Benefit/cost ratio - base 7.0
Benefit/cost ratio - max 11.7Therapeutics and Clinical Risk Management 2006:2(2) 225
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vaccination of the healthy working population aged 18 to
50 years against influenza in a variety of settings is cost-
effective during most influenza seasons (Das Gupta and
Guest 2002; Lee et al 2002). These findings have been
confirmed by double blind, randomized, placebo controlled
studies performed on adult workers in good health (Nichol
et al 1995; Demicheli et al 2000; Postma et al 2002). The
American Center for Disease Control and Prevention
showed that the benefit of vaccination of healthy people of
age < 65 years, is optimized when a vaccine strain chosen
that matches the strain responsible for disease outbreaks in
that year. Elsewhere, economic modelling has been used to
indicate the pricing of a novel, nasal delivery system for an
influenza vaccine to enable programs using this system to
break even financially (Nichol et al 2003).
The benefit of an influenza vaccination program does
not end with the vaccinated person but extends to people
who are not vaccinated because they are less likely be
infected, with a further gain for the structure that promotes
the vaccination program (herd immunization), and fewer
new cases. When the number of vaccinated people increases,
the number of people who become ill decrease and the
possibility of getting infected also drops. This is called herd
immunity (Warburton et al 1972; Webster 2000; Brisson and
Edmunds 2003) in epidemiology and “positive externalities”
(Berger and Szucs 1999; Birch et al 1999; Schnoor 2003)
in economics and is hard to measure, but is surely a further
effect of vaccination that could boost the benefits evaluated
in observational studies like this.
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